Fig. 1: Dynamics of Ebola GP-specific binding antibody concentrations, in log10 scale (ELISA units/mL, EU/mL) for each clinical study from 7 days after the second vaccination. | npj Vaccines

Fig. 1: Dynamics of Ebola GP-specific binding antibody concentrations, in log10 scale (ELISA units/mL, EU/mL) for each clinical study from 7 days after the second vaccination.

From: Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Fig. 1: Dynamics of Ebola GP-specific binding antibody concentrations, in log10 scale (ELISA units/mL, EU/mL) for each clinical study from 7 days after the second vaccination.The alt text for this image may have been generated using AI.

Each subplot represents the antibody dynamics measured in one of the three accredited laboratories: Battelle (left side), Focus (middle) and Q2 Solutions (right side). Each color corresponds to a clinical study (red: EBL1001, dark blue: EBL1003, light blue: EBL1004, orange: EBL2001, turquoise: EBL2002, light green: EBL3001). Solid and dashed lines represent medians in European and African participants, respectively. Circles correspond to Phase I studies and triangles to Phase II studies. Error bars correspond to 25th–75th confidence intervals. The vertical dotted line represents the first year after the first vaccination (309 days after the 2nd vaccination). The horizontal dot-dashed lines represent the LLOQ values considered for each laboratory (36.60, 26.22, and 36.11 EU/mL, at Battelle, Focus, and Q2 Solutions, respectively).

Back to article page